NanoMosaic Announces “Proteomics/Multi-Omics Early Access Program” and First System Sale to Prestigious Boston Hospital

Under this program, NanoMosaic announced its first system sale to a prestigious Boston, MA Longwood area hospital to a CLIA-certified laboratory that develops diagnostic applications aimed at positively impacting the lives of patients. After extensive beta testing, the system performs robustly and strengthens the era of DIY proteomics, allowing end users to functionalize their own chips with capture reagent species such as antibodies, aptamers, nanobodies and/or or species of nucleic acids.

“The Tessie™ platform enables clinical proteomics at the genomic scale.”

“Demand for Tessie™ systems is high, given the scientific advantages, robustness and price of the platform, both in consumables and instrumentation,” said Audrey WarnerHead of NanoMosaic Business Development and Vice President of Investments at Tiger Gene LLC “The company carefully chooses its early access site locations and selects labs that will have a significant impact in the field and whose goals are aligned with of the company’s goals,” Warner concluded.

“The first sale of the Tessie™ system had an impact Boston hospital is an important milestone for the company as it is based on the platform’s streamlined workflow to move seamlessly from biomarker discovery and validation to eventual diagnostic use with the appropriate certifications,” said John Boyce, CEO and co-founder of NanoMosaic and co-founder of Tiger Gene. “The Tessie platform enables clinical proteomics at the scale of genomics,” Boyce concluded.

For information on how to apply for the “Proteomics/Multi-Omics Early Access Program”, please visit and click on “Apply to Early Access Program”.

About NanoMosaic Inc.

NanoMosaic, a Bostonis the only commercial entity to develop and harness the power of nanoneedles, MosaicNeedles™, for protein detection and quantification to develop state-of-the-art assays for biomarker discovery and validation. The NanoMosaic platform, Tessie™, alleviates bottlenecks in proteomics analysis and provides an end-to-end solution that enables first-of-its-kind protein interrogation and multi-omics analysis at the within a single chip in a single run. Proprietary technology enables rapid end-user customization for assay development for proteomics and/or nucleic acid content. The NanoMosaic platform enables researchers to push the frontiers of biomarker discovery and diagnosis.

Contact: Audrey Warner, [email protected]

SOURCE NanoMosaic

About Nereida Nystrom

Check Also

Microsoft withdraws Windows 10 and 11 in Russia • The Register

Microsoft has blocked Windows 10 and 11 from being installed in Russia from the company’s …